

MarketVue®

# Generalized Pustular Psoriasis (GPP)

March 2023



# MarketVue®: Generalized Pustular Psoriasis

## UNDERSTAND THE GPP MARKET

**MarketVue** market landscape reports combine primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.

Every **MarketVue** includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

**Methodology:** Research is supported by 4 qualitative interviews with key opinion leaders (U.S. Dermatologists), a quantitative survey with 27 physicians and secondary research.

**Geographies covered:** United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

## TOPICS COVERED

**EPIDEMIOLOGY:** Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments

**CURRENT TREATMENT:** Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment

**UNMET NEEDS:** Identify opportunities to address treatment or disease management gaps

**PIPELINE ANALYSIS:** Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs

**VALUE AND ACCESS:** Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

## Why MarketVue?

- **PMR-Driven** – Insights informed by qualitative interviews and/or quantitative surveys
- **Senior Team** – Experienced team members (10+ years in pharma market research) lead the research
- **Strategic** – Delivered in a concise and strategic report template vetted by pharmaceutical industry professionals
- **Fresh** – New reports or report refreshes delivered in as little as 15 business days



# MarketVue®: Generalized Pustular Psoriasis

UNDERSTAND THE GPP MARKET

## COMPANIES MENTIONED

- Boehringer Ingelheim
- AnaptysBio
- Shanghai Huaota Biopharmaceutical

## DRUGS MENTIONED

- Calcipotriene
- Tacrolimus
- Acitretin
- Methotrexate
- Cyclosporine
- Apremilast (Otezla)
- Infliximab (Remicade)
- Adalimumab (Humira)
- Secukinumab (Cosentyx)
- Ixekizumab (Taltz)
- Brodalumab (Siliq)
- Guselkumab (Tremfya)
- Risankizumab (Skyrizi)
- Ustekinumab (Stelara)
- Spesolimab (Spevigo)
- Canakinumab (Ilaris)
- Gevokizumab
- Anakinra (Kineret)
- Etanercept (Enbrel)
- Imsidolimab
- HB0034

# MarketVue®: Generalized Pustular Psoriasis

## Table of Contents

<b>1. DISEASE OVERVIEW</b>	<b>5 - 6</b>
A recurrent inflammatory disorder causing pustules across the skin's surface	5
Figure 1.1. Common triggers of GPP flares	5
Figure 1.2. Complications related to GPP	5
Figure 1.3. Frequency and management of GPP symptom flares/exacerbations	6
<b>2. EPIDEMIOLOGY &amp; PATIENT POPULATIONS</b>	<b>7</b>
Disease definition	7
Figure 2.1. G6 prevalent cases of GPP by region	7
Table 2.1. Prevalent and drug-treated populations of GPP in the U.S. and EU5	7
<b>3. CURRENT TREATMENT</b>	<b>8 - 20</b>
Overview	8
Figure 3.1. Treatment goals for GPP	8
Figure 3.2. Current Treatment Patient Share	8
TNF-alpha inhibitors and IL-17 inhibitors are the most commonly used biologics in GPP	9
Figure 3.3. Dermatologist-reported biologic use in GPP patients by drug class	9
Figure 3.4. Preferred second-line biologic classes among surveyed dermatologists	9
Figure 3.5. Percentage of GPP patients who fail first-line biologic therapy	9
Dermatologists choose biologics that are effective in psoriasis	10
Treatment decisions for GPP	11
Figure 3.6 Treatment algorithm for GPP	11
Dermatologists tend to view GPP as a form of psoriasis	12
GPP treatment options are moderately effective	13
Table 3.1. Upside and downsides of currently GPP treatments	13
Off-label GPP treatment options have their limitations	14
An IL-36 biologic is the first approved therapy for GPP	15
Figure 3.7. Results of Ph 2 Trial of a Single IV dose of Spesolimab in Patients with an Acute GPP Flare	15
Figure 3.8. Prior Use of IV Spesolimab (Spevigo) for the treatment of GPP Flare	15
Figure 3.9. Dermatologists' Reported Efficacy of IV Spesolimab in Treating GPP Flare	15
Interviewed dermatologists who have prescribed Spevigo report patients have responded well	16
Figure 3.10. Dermatologists' Likelihood of Prescribing Spesolimab as a SC Maintenance Therapy if Approved	16

# MarketVue®: Generalized Pustular Psoriasis

## Table of Contents

Dermatologists consider efficacy and fast onset of action as top attributes for GPP treatment agents	17
Figure 3.11. Percentage of dermatologists selecting attribute among their top three most important for treatment selection in GPP	17
GPP has a severe impact on psycho-social aspects and the quality of life of patients	18
Figure 3.12. Dermatologists' rating of the impact of GPP on patients	18
Key treatment dynamics that shape disease management and drug use in GPP	19
Table 3.2. Must-know GPP treatment dynamics for now and the future	19
Figure 3.13. Percentage of patients with unsatisfactory outcomes with current GPP treatments	19
The GPP pipeline is limited to IL-36R inhibitors	20
Figure 3.14. Important dynamics of GPP market evolution	20
<b>4. UNMET NEED</b>	<b>21 - 22</b>
Overview	21
Figure 4.1. Top Unmet Needs in GPP	21
Figure 4.2. Dermatologist-reported unmet needs in GPP	21
Physician perspectives on unmet needs in GPP	22
<b>5. PIPELINE ANALYSIS</b>	<b>23 - 26</b>
Overview	23
Figure 5.1. Percent of U.S. dermatologists rating GPP therapy target as "promising"	23
The ongoing IL-36 trial designs indicate intended treatment goals	24
Table 5.1. Comparison of ongoing trials of anti-IL-36R antibodies in GPP	24
Critical spesolimab data will arrive in Q4 of 2022	25
Figure 5.3. Key Dates for the IL-36 Therapies	25
Figure 5.4. Selected Results from Phase 2 GALLOP trial of imsidolimab in adult patients with active GPP	25
Figure 5.5. Trial design of imsidolimab's Phase 3 GEMINI program in GPP	25
Spesolimab may secure another critical corner of the market if approved for maintenance therapy	26
<b>6. VALUE &amp; ACCESS</b>	<b>27 - 28</b>
Overview	27
Table 6.1. Current therapy pricing, U.S. 2023	27
Patient access considerations based on the recent approval of Spevigo	28
Figure 6.1. Resources offered by BI to help facilitate Spevigo patient access	28

# MarketVue®: Generalized Pustular Psoriasis

## Table of Contents

### 7. METHODOLOGY

29 - 30

Primary market research approach

29

Epidemiology methodology

30

Value and access methodology

30

# Meet the REACH Team



**DANIELLE DRAYTON, PhD.**, Dr. Drayton is CEO and Founder of REACH Market Research. She is a seasoned business leader and pharmaceutical market researcher. Prior to founding REACH, Dr. Drayton led the Biopharma Market Assessment business at Decision Resources Group (DRG) comprised of market research, RWD analytics, and consulting business lines. In her 14 years at DRG, she worked with 48 of the top 50 pharmaceutical companies and countless biotech companies that involved exhaustive evaluation of unmet need, target product profiles, commercial potential and new product adoption, and company competitiveness. She also has extensive experience conducting product and market opportunity assessments, portfolio analysis, product and therapeutic area strategy, product valuation and sales forecasting, and pre-launch planning. Dr. Drayton completed a postdoctoral fellowship at the Harvard Medical School, received a Ph.D. in Immunobiology from Yale University, and earned a B.S. in Microbiology and Immunology from the University of Miami (Florida).



**MELISSA CURRAN** is the Director of Product Management at REACH. Melissa has over 10 years of life sciences market research and consulting experience spanning from bespoke strategy consulting to syndicated market research product development and management. Prior to joining REACH, she worked at Decision Resources Group (DRG) for 7 years assisting pharmaceutical and biotechnology commercial teams across the product lifecycle to inform strategic decision making. Melissa is particularly passionate about new product planning and portfolio management, especially in the rare disease space where data can be scarce, and decision-making can be challenging. Specific types of strategic assessments Melissa specializes in include market landscape assessments, commercial opportunity assessment, patient journey mapping, product positioning and TPP optimization, portfolio prioritization, and competitive intelligence. She also has extensive experience working across various market research methodologies including qualitative interviews, quantitative surveys, patient chart audits, real world claims and EHR data, conjoint analysis and secondary research. Melissa received her bachelor's degree in Biology and minor in Business from Providence College.



**MICHAEL HUGHES, MSc, Ph.D.**, Dr. Hughes is the Director of Research at REACH. He has worked in academia, regulatory affairs (NICE) and in RWE and epidemiology consultancies, leading the global epidemiology team at Clarivate (previously Decision Resources Group) for many years. Over that period, he has built numerous new approaches to epidemiological forecasting and imputation, which now form industry best-practice. He has built syndicated and custom epidemiological models and forecasts for many blockbuster drugs across many therapeutic areas, often using a hybrid approach sourcing data from multiple types of dataset and primary market research. He has recently worked on projects in prostate cancer, amyloidosis, anaphylaxis and multi-drug resistant UTIs, among others. He has supported the needs of both big pharma, including Novartis, GSK and Johnson and Johnson, as well as smaller companies and biotechs.

# Meet the REACH Team



**TYLER JAKAB, MPH** is an analyst at REACH Market Research. He is responsible for conducting both primary and secondary market research regarding rare disease therapies to be integrated into market research reports for life science clients. Tyler is a recent graduate of Boston University School of Public Health where he obtained an MPH in Epidemiology of Biostatistics. Prior to joining REACH, he held roles in which he was responsible for health policy analysis, tobacco control research, and health communication. He has extensive experience in data analysis, as well as manuscript and report writing. Tyler also earned a BS in Psychology and Anthropology from the University of North Carolina at Chapel Hill.



**BAYLEY KOOPMAN** is a Research Associate at REACH Market Research. At REACH, Bayley supports both primary and secondary market research through literature reviews and working with qualitative data. He recently graduated from Tufts University with a B.S. in Biology where he studied the interdisciplinary OneHealth approach for public health and the environment. During this time, Bayley founded an early-stage consumer product startup, which became a finalist team in two consecutive Tufts University Entrepreneurship Pitch Competitions. Prior to joining REACH, Bayley also held roles in regulatory affairs in the rare-disease pharmaceutical industry and veterinary practice.



**BRIANA MULLINS** is a current PhD student At NYU School of Medicine studying the immunological progression of disease in psoriatic arthritis. She currently does both laboratory research and computational biology. Previously she earned her undergraduate degree in Biochemistry at New York University (NYU) and worked in the Blaser Lab studying the human microbiome. She also received an MSc. in Population Health at the University College London (UCL) and conducted antibiotic prescription research using the UK THIN Database. Before starting her PhD Briana worked at Decision Resources Group as an Associate Epidemiologist.